Multiple Myeloma | Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30) Emerging data with mezigdomide/dexamethasone for relapsed/refractory MM (13:22) Early results with and ongoing investigations of mezigdomide/dexamethasone in combination with a proteasome inhibitor (29:54) CME information and select publications